Mainz Biomed N.V. Ordinary Shares (MYNZ) is a publicly traded Healthcare sector company. As of May 21, 2026, MYNZ trades at $0.84 with a market cap of $10.56M and a P/E ratio of -0.50. MYNZ moved +5.07% today. Year to date, MYNZ is -47.57%; over the trailing twelve months it is -81.89%. Its 52-week range spans $0.55 to $16.04. Analyst consensus is hold with an average price target of $0.00. Rallies surfaces MYNZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Mainz Biomed Demonstrates 100% Sensitivity and 95% Specificity of mRNA Pancreatic Cancer Test: Mainz Biomed will present at Digestive Disease Week 2026 in Chicago a poster on its blood-based mRNA signature test for pancreatic ductal adenocarcinoma with 100% sensitivity and 95% specificity. The findings confirm the algorithm’s biomarker selection and advance PancAlert PCR multiplex screening toward clinical readiness for early-stage pancreatic cancer detection.
| Metric | Value |
|---|---|
| Price | $0.84 |
| Market Cap | $10.56M |
| P/E Ratio | -0.50 |
| EPS | $-1.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.04 |
| 52-Week Low | $0.55 |
| Volume | 5.25M |
| Avg Volume | 0 |
| Revenue (TTM) | $537.08K |
| Net Income | $-16.29M |
| Gross Margin | 0.00% |
3 analysts cover MYNZ: 0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is hold. Average price target: $0.00.